PCI Biotech Holding ASA
Oslo Stock Exchange PCIB.OL
PCI Biotech Holding ASA Price to Sales Ratio (P/S) on January 14, 2025: 13.85
-
PCI Biotech Holding ASA 52-week high Price to Sales Ratio (P/S) is 34.24 on May 28, 2024, which is 147.34% above the current Price to Sales Ratio (P/S).
-
PCI Biotech Holding ASA 52-week low Price to Sales Ratio (P/S) is 13.32 on December 30, 2024, which is -3.78% below the current Price to Sales Ratio (P/S).
-
PCI Biotech Holding ASA average Price to Sales Ratio (P/S) for the last 52 weeks is 20.65.
| Date | Price to Sales Ratio (P/S) | Price to Book Ratio (P/B) | Dividend Yield | Free Cash Flow Yield |
|---|
| CEO | Mr. Ronny Skuggedal |
| IPO Date | June 23, 2008 |
| Location | Norway |
| Headquarters | UllernchaussEen 64 |
| Employees | 6 |
| Sector | Health Care |
| Industries | |
PCI Biotech Holding ASA, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for the treatment of cancer through its photochemical internalization (PCI) technology platform. The company develops anticancer paradigms, including fimaCHEM, a chemotherapeutics for treatment of cancer; fimaVACC, a T-cell induction technology for therapeutic vaccination, which is in Phase I clinical study; and fimaNAc, a nucleic acid therapeutics delivery technology, which is in pre-clinical study. It also offers Amphinex, a photosensitiser fimaporfin. The company has collaborative research programs with Bavarian Nordic, BioNTech, Phio Pharmaceuticals, DCprime, eTheRNA immunotherapies, IMV, and Aposense. PCI Biotech Holding ASA is based in Oslo, Norway.
Past 5 years
StockViz Staff
January 15, 2025
Any question? Send us an email